OPKO Health, Inc. Excess Tax Benefit from Share-based Compensation, Operating Activities
OPKO Health, Inc. (OPK) reported Excess Tax Benefit from Share-based Compensation, Operating Activities of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-18.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities · last filed 2021-02-18
- OPKO Health, Inc. excess tax benefit from share-based compensation, operating activities for fiscal 2020 was $0.00.
- OPKO Health, Inc. excess tax benefit from share-based compensation, operating activities for fiscal 2019 was $0.00.
- OPKO Health, Inc. excess tax benefit from share-based compensation, operating activities for fiscal 2018 was $0.00.
- OPKO Health, Inc. excess tax benefit from share-based compensation, operating activities for fiscal 2017 was $0.00.
| Period end | Excess Tax Benefit from Share-based Compensation, Operating Activities 12 month |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-02-18 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-18 |
| 2018-12-31 | $0.00 10-K · filed 2021-02-18 |
| 2017-12-31 | $0.00 10-K · filed 2020-03-02 |
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 |
| 2015-12-31 | $0.00 8-K · filed 2019-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |